Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non–Small-Cell Lung Cancer

Published:2015-09 Issue:5 Volume:11 Page:356-362
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Carroll Nikki M.¹,Delate Thomas¹,Menter Alex¹,Hornbrook Mark C.¹,Kushi Lawrence¹,Aiello Bowles Erin J.¹,Loggers Elizabeth T.¹,Ritzwoller Debra P.¹

Affiliation:

1. Kaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA

Abstract

Findings here confirm the need for adherence to clinical recommendations for judicious use of carboplatin-paclitaxel-bevacizumab, but provide reassurance regarding the relative risk.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2014.002980

Reference40 articles.

1. Cancer statistics, 2012

2. FDA Drug Approval Summary: Bevacizumab (Avastin®) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell Lung Cancer

3. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

4. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

5. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer;BioDrugs;2023-09-25

2. Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer;Cancer Treatment and Research Communications;2023

3. Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis;BMC Medicine;2020-10-23

4. Collaborating on Data, Science, and Infrastructure: The 20-Year Journey of the Cancer Research Network;eGEMs (Generating Evidence & Methods to improve patient outcomes);2019-03-29

5. Exploring Big Data in Hematological Malignancies: Challenges and Opportunities;Current Hematologic Malignancy Reports;2016-05-13